Pharmaceutical Powder Baricitinib 99% Purity Baricitinib Powder Raw Powder Baricitinib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung--aricitinib
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Baricitinib
• Name: Baricitinib Powder
• Appearance: White Powder
• Color: White Color
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical;Anti-Rheumatic
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No: 1187594-09-7
• Mf: C16h17n7o2s
• MW: 371.41700
• Boiling Point: 707.2
• Density: 1.56
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 5000kg/Month

Product Description

Pharmaceutical Powder Baricitinib 99% Purity Baricitinib Powder Raw Powder Baricitinib

Product Description

Product Details

Product name	Baricitinib
Cas number	1187594-09-7
Appearance	White powder
Melting point	[707.2]
MF	C16H17N7O2S
MW	371.41700
Density	1.56

Baricitinib is a drug for the treatment of rheumatoid arthritis (RA) in adults whose disease was not well controlled using RA medications called tumor necrosis factor (TNF) antagonists. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2. The drug is approved for use in the European Union and the United States.

Application&Function

Baricitinib (baricitinib) obtained FDA emergency authorization (EUA) to be used in combination with Redecivir to treat patients who require supplemental oxygen, intubation ventilation or extracorporeal membrane oxygenation, children over 2 years of age, or adult hospitalized patients with new coronary pneumonia or Suspected patient. The FDA emergency authorization is based on a clinical trial (ACTT-2) conducted by the National Institute of Allergy and Infectious Diseases (ACTT-2). Compared with radcivir monotherapy, baritinib is combined with radcivir. It can reduce the patient's recovery time during the 29-day treatment period.

Specification